azacitidine has been researched along with sirolimus in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Dai, Q; Fang, JY; Li, XQ; Sun, DF; Tian, XQ; Xiong, H; Zhang, YJ; Zhao, SL | 1 |
| Goodson, H; Helquist, P; Huegel, KL; Hulett, TW; Vaughan, KT; Wehrmann, ZT; Wiest, O | 1 |
| Boddy, N; Burrows, F; Pallis, M; Russell, N; Seedhouse, C; Whittall, A | 1 |
| Bechelli, J; Becker, MW; Chen, R; Ifthikharuddin, JJ; Jordan, CT; Liesveld, JL; Minhajuddin, M; Mulford, D; O'Dwyer, K; Phillips, GL; Rosell, K; Walker, A | 1 |
1 review(s) available for azacitidine and sirolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for azacitidine and sirolimus
| Article | Year |
|---|---|
A phase I study of decitabine and rapamycin in relapsed/refractory AML.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Pilot Projects; Recurrence; Sirolimus | 2013 |
5 other study(ies) available for azacitidine and sirolimus
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Combined inhibition of Dnmt and mTOR signaling inhibits formation and growth of colorectal cancer.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Azacitidine; Cell Cycle; Cell Cycle Proteins; Cell Proliferation; Colorectal Neoplasms; DNA (Cytosine-5-)-Methyltransferases; Drug Synergism; HCT116 Cells; Humans; Immunohistochemistry; Mice; Phosphoproteins; Phosphorylation; Protein Kinases; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Tumor Burden | 2009 |
Quantitative comparison of the efficacy of various compounds in lowering intracellular cholesterol levels in Niemann-Pick type C fibroblasts.
Topics: Azacitidine; beta-Cyclodextrins; Cells, Cultured; Child; Child, Preschool; Chloroquine; Chlorpromazine; Cholesterol; Decitabine; Dose-Response Relationship, Drug; Drug Synergism; Female; Fibroblasts; Humans; Hydroxamic Acids; Indoles; Intracellular Space; Male; Microscopy, Fluorescence; Mutation; Niemann-Pick Disease, Type C; Panobinostat; Sirolimus; Vorinostat | 2012 |
Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cells.
Topics: Acute Disease; Adenine Nucleotides; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Azacitidine; Cell Line, Tumor; Cell Survival; Clofarabine; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Etoposide; Flavonoids; Heterocyclic Compounds, 4 or More Rings; Humans; Leukemia, Myeloid; Piperidines; Purines; RNA Polymerase II; RNA, Neoplasm; Roscovitine; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
News products to avoid.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Azacitidine; Decitabine; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Everolimus; Ferrosoferric Oxide; Gefitinib; Hematinics; Humans; Imidazoles; Indazoles; Oxonic Acid; Pyridines; Quinazolines; Risk Assessment; Risk Factors; Sirolimus; Tegafur | 2014 |